Sigmoid take-off as an anatomical landmark for rectal cancer reclassification: impact on multimodal treatment and long-term oncological outcomes. A multicenter retrospective national cohort study (MOLINO study collaborative work)
This multicenter retrospective study demonstrates that systematically applying the sigmoid take-off as an anatomical landmark on MRI reclassifies approximately 23% of tumors previously managed as rectal cancer as sigmoid cancer, thereby reducing unnecessary neoadjuvant therapy without compromising perioperative safety or long-term oncological outcomes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The Great Map Makeover: Why Location Matters in Cancer Care
Imagine your body is a bustling city, and the digestive tract is the main highway running through it. Sometimes, trouble starts on this road in the form of a tumor. For a long time, doctors have had to decide exactly where on this highway the trouble began, because the rules for fixing it change depending on the neighborhood. If the trouble is in the "Rectum District" (the very end of the road, close to the exit), the rules are strict: you often need to blast the area with radiation and chemotherapy before surgery to shrink the problem. But if the trouble is in the "Sigmoid District" (just a little further up the road), the rules are more relaxed, and surgery alone might be enough.
The problem is that the border between these two districts has been blurry. For years, doctors used different landmarks to draw the line—some measured from the exit, others looked for a specific fold in the tissue. It was like trying to find a street address when everyone used a different map. This confusion meant some people got the "heavy artillery" treatment (radiation and chemo) even though they didn't need it, while others might have missed out on the right care. Scientists have been looking for a single, perfect landmark to settle the debate, and they found one: a specific curve in the road called the "sigmoid take-off." Think of it as the exact spot where the highway makes a sharp turn away from the spine. If a tumor is above this turn, it's Sigmoid; if it's below, it's Rectal. Getting this right matters because it stops unnecessary treatment and helps patients recover faster.
The MOLINO Study: Redrawing the Lines
In a massive study called the MOLINO project, a team of doctors across Spain decided to test this new "turning point" map. They looked back at the records of 1,441 patients who had surgery for rectal cancer between 2017 and 2023. The researchers took a fresh look at the MRI scans of every single patient, using the "sigmoid take-off" (STO) as their ruler. They asked a simple question: "If we use this new, strict definition, do any of these tumors actually belong to the Sigmoid neighborhood instead of the Rectum?"
The answer was a big surprise. The new map reclassified 22.7% of the tumors. That means nearly one out of every four patients who had been treated as if they had rectal cancer actually had sigmoid cancer. These patients had been getting the heavy pre-surgery radiation and chemotherapy, but according to the new rules, they didn't need it. The study suggests that by using this landmark, doctors could have spared these patients from unnecessary treatment.
But did this change in classification mess up the results? Did avoiding the heavy treatment make the cancer come back? The data says no. In fact, the patients in the "new sigmoid" group had an easier time overall. They spent less time in the hospital (a median of 5 days compared to 6 days for the upper rectum group and 8 days for the lower rectum group). They also had fewer complications after surgery. Only 4.5% of the new sigmoid group had a leak at the surgical connection site, compared to 11.7% in the upper rectum group and 7.5% in the lower rectum group.
Most importantly, the long-term safety was just as good. Even though the "new sigmoid" patients received less radiation and chemo, their chances of the cancer coming back (disease-free survival) and their overall survival rates were comparable to the patients who were definitely rectal cancer. The study found no difference in survival rates between the groups (p = 0.653 for overall survival and p = 0.831 for disease-free survival).
The researchers also noted that the old way of doing things might have been "over-treating" people. In this study, 45.2% of the newly reclassified sigmoid patients still received neoadjuvant therapy (treatment before surgery), but this was significantly less than the 81.9% of lower rectum patients who got it. The study suggests that sticking to the old, blurry definitions might have led to many patients getting toxic treatments they didn't need, while the new, sharp definition of the sigmoid take-off allows for a more precise, safer, and equally effective approach.
In short, this paper argues that it's time to update the maps. By using the sigmoid take-off as the official border, doctors can stop guessing, avoid blasting patients with unnecessary radiation, and still keep everyone safe from cancer. It's a win for precision: fewer side effects, shorter hospital stays, and the same great results.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.